Wyeth expects to receive an FDA “approvable” letter for its
Effexor XR follow-on (venlafaxine extended-release) Pristiq
(desvenlafaxine), CEO Robert Essner said during Morgan Stanley
CEOs Unplugged Conference Jan. 3.
Original post by Google Inc.
0 Responses to “Wyeth Anticipates "Approvable" Letter For Effexor XR Follow-On”